tariquidar has been researched along with isoniazid in 1 studies
| Studies (tariquidar) | Trials (tariquidar) | Recent Studies (post-2010) (tariquidar) | Studies (isoniazid) | Trials (isoniazid) | Recent Studies (post-2010) (isoniazid) |
|---|---|---|---|---|---|
| 210 | 16 | 138 | 21,815 | 960 | 4,493 |
| Protein | Taxonomy | tariquidar (IC50) | isoniazid (IC50) |
|---|---|---|---|
| Myeloperoxidase | Homo sapiens (human) | 4.85 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 8.29 | |
| Putative FAD-containing monooxygenase MymA | Mycobacterium tuberculosis H37Rv | 4.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Back, DJ; Bertel Squire, S; Chandler, B; Hartkoorn, RC; Khoo, SH; Owen, A; Ward, SA | 1 |
1 other study(ies) available for tariquidar and isoniazid
| Article | Year |
|---|---|
Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.
Topics: Antitubercular Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Cells, Cultured; Colorimetry; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Ethambutol; Humans; Indicators and Reagents; Isoniazid; Macrophages; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxazines; Phagocytosis; Quinolines; Rifampin; Spectrometry, Fluorescence; Tuberculosis; Xanthenes | 2007 |